Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)92-98
Number of pages7
JournalEuropean Journal of Cancer
Volume91
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • Non-small cell lung cancer
  • Tyrosine kinase inhibitor
  • QT interval
  • Disease flare
  • Drug monitoring
  • CELL LUNG-CANCER
  • 1ST-LINE TREATMENT
  • PHASE-3 TRIAL
  • OPEN-LABEL
  • GEFITINIB
  • ADENOCARCINOMA
  • DACOMITINIB
  • INHIBITOR
  • ERLOTINIB
  • INTERVAL

Cite this

@article{beca04c7de2248918c48fdba4bd3f257,
title = "Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring",
keywords = "Non-small cell lung cancer, Tyrosine kinase inhibitor, QT interval, Disease flare, Drug monitoring, CELL LUNG-CANCER, 1ST-LINE TREATMENT, PHASE-3 TRIAL, OPEN-LABEL, GEFITINIB, ADENOCARCINOMA, DACOMITINIB, INHIBITOR, ERLOTINIB, INTERVAL",
author = "Mart Schiefer and Hendriks, {Lizza E. L.} and Dinh Dinh and Ulrich Lalji and Dingemans, {Anne-Marie C.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.ejca.2017.12.011",
language = "English",
volume = "91",
pages = "92--98",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER SCI LTD",

}

Current perspective: Osimertinib-induced QT prolongation : new drugs with new side-effects need careful patient monitoring. / Schiefer, Mart; Hendriks, Lizza E. L.; Dinh, Dinh; Lalji, Ulrich; Dingemans, Anne-Marie C.

In: European Journal of Cancer, Vol. 91, 01.03.2018, p. 92-98.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Current perspective: Osimertinib-induced QT prolongation

T2 - new drugs with new side-effects need careful patient monitoring

AU - Schiefer, Mart

AU - Hendriks, Lizza E. L.

AU - Dinh, Dinh

AU - Lalji, Ulrich

AU - Dingemans, Anne-Marie C.

PY - 2018/3/1

Y1 - 2018/3/1

KW - Non-small cell lung cancer

KW - Tyrosine kinase inhibitor

KW - QT interval

KW - Disease flare

KW - Drug monitoring

KW - CELL LUNG-CANCER

KW - 1ST-LINE TREATMENT

KW - PHASE-3 TRIAL

KW - OPEN-LABEL

KW - GEFITINIB

KW - ADENOCARCINOMA

KW - DACOMITINIB

KW - INHIBITOR

KW - ERLOTINIB

KW - INTERVAL

U2 - 10.1016/j.ejca.2017.12.011

DO - 10.1016/j.ejca.2017.12.011

M3 - Article

VL - 91

SP - 92

EP - 98

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -